Introduction
No major advances have been made in improving overall survival for glioblastoma (GBM) in almost 100 years. The currentNo major advances have been made in improving overall survival for glioblastoma (GBM) in almost 100 years. The currentstandard of care (SOC) for GBM involves immediate surgical resection followed by radiotherapy with concomitanttemozolomide chemotherapy. Corticosteroid (dexamethasone) is often prescribed to GBM patients to reduce tumor edemaand inflammation. The SOC disrupts the glutamate–glutamine cycle thus increasing availability of glucose and glutaminein the tumor microenvironment. Glucose and glutamine are the prime fermentable fuels that underlie therapy resistance anddrive GBM growth through substrate level phosphorylation in the cytoplasm and the mitochondria, respectively.
